V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160015600 | 160016166 | 1.6 | 65 | Curative (C) | 2021-01-10 | 2021-05-19 | Vincristine (weekly) | N | N | IRINOTECAN + TEMOZOLOMIDE | 101463599 |
| 160015601 | 160016167 | 1.67 | 37 | null | 2018-01-24 | 2018-04-18 | DACTINOMYCIN + CYCLO + VINCRISTINE | 02 | null | CARBOPLATIN + ETOPOSIDE | 100749332 |
| 160015611 | 160016169 | 1.78 | 87.6 | Neo-adjuvant (N) | 2017-07-22 | 2017-07-22 | Niraparib | 01 | N | ETOP 13-18 BEAT-MESO TRIAL | 101580672 |
| 160015618 | 160016170 | 1.86 | 75 | null | 2020-09-22 | 2021-03-09 | CONFIRM TRIAL | 02 | null | EW EUROEWING 2012 ARM A VAC | 101108126 |
| 160015623 | 160016172 | 1.61 | 17.4 | null | 2018-02-25 | 2018-12-03 | ICE + GCSF | null | null | OLARATUMAB | 101534230 |
| 160015642 | 160016174 | 1.63 | 70.8 | null | 2017-10-13 | 2017-10-15 | Doxorubicin + Ifosfamide | 02 | null | TRIAL | 100560198 |
| 160015645 | 160016175 | 1.8 | 85.2 | null | 2020-03-10 | 2020-04-15 | Olaparib | null | null | PEMBROLIZUMAB | 101040941 |
| 160015651 | 160016176 | null | 96.6 | null | null | 2019-10-21 | NB HRNBL-1 COJEC Ind COURSE B | 02 | null | IPILIMUMAB | 101700481 |
| 160015669 | 160016177 | 1.79 | 125.3 | Adjuvant (A) | 2017-02-14 | 2017-02-14 | GEMCITABINE | 01 | N | RUCAPARIB | 101035218 |
| 160015678 | 160016178 | 0 | 40.5 | null | 2019-02-03 | 2019-03-14 | DACARBAZINE + GEMCITABINE | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100269210 |
| 160015679 | 160016179 | 1.68 | 103 | null | 2017-05-01 | 2017-07-05 | FLUOROURACIL + IRINOTECAN | 02 | null | NB HRNBL-1 BUMEL MAT | 100494943 |
| 160015680 | 160016180 | 1.57 | 75 | null | 2018-09-27 | 2018-12-02 | Ifosfamide | 01 | null | STS RHABDO VIT0910 VINC IRINO TEMOZ | 100092291 |
| 160015684 | 160016181 | 1.6 | 95.3 | null | 2017-05-21 | 2018-01-31 | PROMISE-MESO TRIAL | 02 | null | ETOPOSIDE + IFOSFAMIDE | 101515064 |
| 160015696 | 160016182 | null | 78.5 | 03 | null | 2020-07-21 | Trial Unspecified | Y | N | IFOSFAMIDE | 100650157 |
| 160015698 | 160016183 | 1.79 | 82 | null | 2018-09-28 | 2018-10-13 | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 02 | null | NIRAPARIB | 101424905 |
| 160015700 | 160016184 | 1.6 | 84.5 | null | 2018-05-13 | 2018-05-23 | STS Rhabdo RMS 2005 Vin Cyclo | 01 | null | PEMBROLIZUMAB | 100400047 |
| 160015703 | 160016185 | 1.67 | 86.2 | Palliative (P) | 2016-10-16 | 2017-01-07 | Etoposide oral | 02 | N | NB HRNBL | 100934751 |
| 160015710 | 160016186 | 1.54 | 74 | null | 2020-02-07 | 2020-06-08 | ETOP 13-18 BEAT-meso Trial | 02 | null | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 100023699 |
| 160015712 | 160016187 | 0 | 63.3 | Curative (C) | 2021-03-15 | 2021-04-28 | null | 02 | N | GEMCITABINE | 100083795 |
| 160015721 | 160016188 | 1.43 | 87.35 | null | 2020-12-24 | 2021-05-22 | LENALIDOMIDE | 02 | null | GEMCITABINE | 101287278 |
| 160015726 | 160016189 | 1.75 | 80 | Palliative (P) | 2016-03-03 | 2016-10-04 | null | 02 | N | IFOSFAMIDE | 100531820 |
| 160015728 | 160016190 | 1.79 | null | Palliative (P) | 2018-01-17 | 2018-01-17 | VAI (Ifos 3g/m2) | 02 | N | OLARATUMAB | 101252207 |
| 160015729 | 160016191 | 1.65 | 40.45 | Curative (C) | null | 2017-03-04 | Olaparib | 99 | Y | ETOPOSIDE + IFOSFAMIDE | 101762522 |
| 160015732 | 160016192 | 1.82 | 63.3 | Curative (C) | 2019-12-30 | 2020-02-05 | ATOMIC-MESO TRIAL | 02 | N | ETOPOSIDE | 100872779 |
| 160015739 | 160016193 | 1.56 | 18 | null | 2018-06-07 | 2018-06-17 | STS Rhabdo VIT0910 Vinc Irino Temoz | null | null | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 100125940 |
| 160015740 | 160016194 | 1.65 | 49 | Curative (C) | 2021-07-20 | 2021-12-10 | Trial Unspecified | 01 | N | CISPLATIN | 100638111 |
| 160015741 | 160016195 | 1.65 | 57.8 | Neo-adjuvant (N) | 2019-10-29 | 2019-10-29 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 101135079 |
| 160015744 | 160016196 | 1.56 | 83.4 | null | 2018-12-29 | 2019-02-17 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | null | GEMCITABINE | 101633964 |
| 160015745 | 160016197 | 0 | 70.7 | null | 2019-06-15 | 2019-06-15 | null | 02 | null | NB RELAPSED IRINOTECAN AND TEMOZOLOMIDE | 100977969 |
| 160015746 | 160016198 | 1.87 | 67.1 | null | 2021-12-28 | 2022-02-23 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | null | IVA | 101622762 |
| 160015747 | 160016199 | 1.67 | 60.8 | Palliative (P) | 2017-04-02 | 2017-04-02 | EW EuroEwing 2012 Arm A VAC | 02 | N | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 100561282 |
| 160015749 | 160016200 | 1.82 | 40.4 | Palliative (P) | null | 2020-02-10 | Ifosfamide PVI 1g/m2 14day | 02 | N | IVA | 101212494 |
| 160015750 | 160016201 | 1.78 | 58.9 | Curative (C) | 2017-12-20 | 2018-06-26 | EW EuroEwing 2012 Arm B VC | 02 | N | RMS 2005 TRIAL | 101263802 |
| 160015751 | 160016202 | 1.63 | 100.2 | null | 2019-06-13 | 2019-06-13 | null | null | null | GEMCITABINE | 100714421 |
| 160015752 | 160016203 | 1.57 | 73.6 | Palliative (P) | 2022-02-27 | 2022-02-28 | MELPHALAN | 02 | null | ABIRATERONE | 101544954 |
| 160015755 | 160016204 | 0.82 | 105.8 | Neo-adjuvant (N) | 2018-07-25 | 2018-07-27 | EW EuroEwing 2012 Arm B VC | 01 | N | NOT MATCHED | 100305949 |
| 160015757 | 160016205 | 1.61 | 10.5 | Curative (C) | 2019-08-22 | 2019-08-29 | Doxorubicin + Ifosfamide | 02 | N | NIRAPARIB | 100425329 |
| 160015761 | 160016206 | 1.63 | 86 | Curative (C) | 2020-04-11 | 2020-04-25 | Pazopanib | 02 | N | PEMBROLIZUMAB | 100995533 |
| 160015769 | 160016207 | null | 57.9 | null | 2017-11-04 | 2018-03-18 | ETOP 13-18 BEAT-meso Trial | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 101344878 |
| 160015771 | 160016208 | 1.65 | 19.6 | Palliative (P) | 2021-12-02 | 2021-12-02 | CYCLOPHOSPHAMIDE + VINORELBINE | 02 | N | STS RHABDO VIT0910 VINC IRINO TEMOZ | 101650294 |
| 160015772 | 160016209 | 1.82 | 67.3 | Palliative (P) | 2016-12-22 | 2016-12-26 | EURO-EWING | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100283352 |
| 160015775 | 160016210 | 1.6 | 121 | Palliative (P) | null | 2020-02-19 | GEMCITABINE | 02 | N | CISPLATIN + DOXORUBICIN + METHOTREXATE | 101406357 |
| 160015789 | 160016211 | 1.82 | 71.6 | Neo-adjuvant (N) | 2016-11-08 | 2017-03-06 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | EW EUROEWING 2012 ARM B IE | 100124778 |
| 160015791 | 160016212 | 1.84 | 56.6 | null | 2018-08-07 | 2018-08-15 | Niraparib | 02 | null | NIRAPARIB | 101717290 |
| 160015794 | 160016213 | 0 | 75 | Curative (C) | 2018-05-07 | 2019-04-19 | Niraparib | 02 | N | NIRAPARIB | 100547941 |
| 160015799 | 160016214 | null | 81.5 | null | 2016-11-19 | 2016-11-26 | Cyclophosphamide + Topotecan | 02 | null | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 100988419 |
| 160015807 | 160016215 | 1.8 | 16.8 | Palliative (P) | 2019-09-29 | 2019-10-13 | EW EuroEwing 2012 Arm B IE | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100864853 |
| 160015809 | 160016216 | 1.67 | 8.8 | Curative (C) | 2019-10-18 | 2020-06-01 | IPO | 02 | N | IVA | 100276551 |
| 160015810 | 160016217 | 1.67 | 45.9 | null | 2017-02-07 | 2017-02-20 | Docetaxel 75mg/m2 (21 day) | 02 | null | NB RELAPSED CCLG GUIDELINES TVD | 101421285 |
| 160015817 | 160016218 | 0 | 98.5 | Palliative (P) | 2018-10-28 | 2019-04-03 | PEMBROLIZUMAB | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100532897 |